Healthcare Edge – Page 12 – ExecEdge

Eterna Therapeutics Teams with Lineage Cell on Transplant Therapies

Eterna Therapeutics Teams with Lineage Cell on Transplant Therapies

By Daniella Parra Eterna Therapeutics Inc. (Nasdaq: ERNA) is partnering with Lineage Cell Therapeutics, Inc. to develop stem cell lines for central nervous system diseases, the company said. Eterna’s mRNA gene-editing approach and Lineage’s expertise in gene editing aim to...

Plus Therapeutics Trialing Cancer Treatment for Cerebrospinal Fluid

Plus Therapeutics Trialing Cancer Treatment for Cerebrospinal Fluid

By Karen E. Roman Plus Therapeutics, Inc. (Nasdaq: PSTV) announced treatment of the first patient in Part B of a trial for the treatment of leptomeningeal metastases from solid tumors. Leptomeningeal metastases are complication of cancer in which the primary cancer spreads to...

Eterna Therapeutics Appoints Dorothy Clarke to Board of Directors

Eterna Therapeutics Appoints Dorothy Clarke to Board of Directors

By Healthcare Edge Editorial Staff Eterna Therapeutics Inc. (Nasdaq: ERNA), a life science company focused on the potential of mRNA cell engineering, said it appointed Dorothy Clarke to its board of directors. Dorothy’s extensive experience will continue to help deliver...

Comera Study Shows Caffeine’s Ability to Reduce Viscosity in Antibodies

Comera Study Shows Caffeine’s Ability to Reduce Viscosity in Antibodies

By Daniella Parra Comera Life Sciences Holdings (Nasdaq: CMRA) said it published data showing caffeine’s potential to reduce viscosity in subcutaneous formulations of monoclonal antibodies. The studies demonstrated caffeine’s positive influence on pharmacokinetics and its compatibility with monoclonal antibody ipilimumab,...

Input your search keywords and press Enter.